Ronald Dubner
Corporate Officer/Principal presso Xalud Therapeutics, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Stephen D. Collins | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Mike Huston | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Paul Manning | M | 68 |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Jayson M. Rieger | M | 48 |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Sean Stalfort | M | 53 |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Brendan O’Leary | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | 3 anni |
Charles Cleeland | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Gerald Gebhart | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Daniel Lammertse | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 9 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Ronald Dubner
- Contatti personali